Case Report ARTICLE
ASTHMA,URTICARIA AND OMALIZUMAB IN CHILDREN. REFLECTIONS FROM A CLINICAL CASE REPORT.
- 1Department of Clinical Medicine, Public Health, Life Sciences and the Environment, University of L'Aquila, Italy
Urticaria of childood is rare and more uncommon is its persistence.Comorbidities are associated with CSU in children, among these asthma, allergic rhinitis or atopic dermatitis, while many children with CSU have a family history of atopy.
Therapeutic approach to CSU in children is the same recommended in international guidelines for management of chronic urticaria in adults.
In the European Union, according to European Medicine Agency, Omalizumab is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. Furthermore in children (6 to <12 years of age) is indicated as add-on therapy to improve asthma control.The treatment of children with urticaria under the age of 12 represents a therapeutic “limbo”, being possible to administer omalizumab only “off label”.
Keywords: Chronic spontaneous urticaria (CSU), Omalizumab (Xolair), Precision Medicine, Immunoglobulin E (IgE), Translational Medical Research, Children, Hypersensitivity, Asthma
Received: 27 Nov 2018;
Accepted: 10 May 2019.
Edited by:Claudio Pignata, University of Naples Federico II, Italy
Reviewed by:Markus Weckmann, Universität zu Lübeck, Germany
Mario Sanchez-Borges, Department of Allergy and Clinical Immunology, El Ávila Clinic, Venezuela
Copyright: © 2019 SIRUFO, GINALDI and DE MARTINIS. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. MASSIMO DE MARTINIS, Department of Clinical Medicine, Public Health, Life Sciences and the Environment, University of L'Aquila, L’Aquila, 67010, Abruzzo, Italy, email@example.com